Isothiocyanate / NRF2 activator

Plain-language summaryIntrigue 72 / 100

Sulforaphane is an isothiocyanate from broccoli sprouts that potently activates Nrf2, the master regulator of antioxidant gene expression. Has shown chemopreventive effects in cancer research and is being studied for autism spectrum disorder. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

57/100

Best-in-class natural Nrf2 probe with multi-indication clinical signal but mature literature limits novelty score

Look, sulforaphane is the reference compound for Nrf2 activation research, and if you’re working in that space you already know this. The Talalay group at Johns Hopkins pulled it from broccoli in 1992, characterized the Keap1-Nrf2 mechanism, and that paper essentially defined a field. Thirty-plus years later, there are over 80 interventional trials across cancer chemoprevention, metabolic disease, autism spectrum disorder, schizophrenia, and airway inflammation. That breadth is real and it matters for how we think about this compound’s place in a serious research library.

The mechanism is genuinely interesting even if it’s no longer novel. The electrophilic modification of reactive cysteines on Keap1 is elegant chemistry. Sulforaphane modifies C151, C273, and C288 on Keap1 simultaneously, destabilizing the complex and releasing Nrf2 for nuclear translocation. What we like about this compound is that it’s not just an Nrf2 activator. It independently suppresses NF-kappaB via IkappaB-alpha stabilization, and the mercapturic acid metabolites SFN-cys and SFN-NAC inhibit class I and class II HDACs. Thats three mechanistically distinct pharmacological levers from one small molecule, which is more than most dietary-origin compounds can honestly claim.

The bench value is hard to argue with. Sulforaphane at low micromolar concentrations is what you reach for when you want to activate the Keap1-Nrf2-ARE axis in cell culture. Nothing from a natural source comes close on potency. The standardized NQO1 inducer assays put it at 13-fold over curcumin, 18-fold over silymarin, and over 100-fold over resveratrol. As a pharmacological probe, it defines what is possible for dietary-origin Nrf2 activation, and that clean probe value is load-bearing for the bench score here.

The overall lands where it does because novelty is genuinely low. The mechanism has been described, debated, and confirmed over three decades. The ASD signal from Singh et al. (2014) and the Axelsson type 2 diabetes trial from 2017 are interesting human data but effect sizes, while real, are modest and neither result has driven regulatory action. The schizophrenia angle via oxidative stress and NRF2 dysregulation is intriguing but still early and underpowered. We dont have a clinically approved indication, which keeps the translational ceiling below what the preclinical depth might suggest.

For investigators running cytoprotection, Nrf2 pathway, or electrophilic signaling programs, sulforaphane is an indispensable probe. If you’re trying to understand Keap1 biology you need this compound. The differentiation advantage over alternatives is clearest here: curcumin is pharmacologically messy and poorly bioavailable, DIM works downstream at a different node, bardoxolone methyl is pharmacologically heavier and harder to work with at bench scale. None of them give you the clean Keap1 signal that sulforaphane provides at reproducible low micromolar concentrations. That’s real, and that’s why this scores above the established-mature crowd even though the novelty window closed some time ago.

Novelty: 35
Mechanism promise: 55
In-category differentiation: 62
Evidence quality: 65
Translational signal: 60
Research bench value: 74

Rationale Sulforaphane is the reference Nrf2 activator with 30-plus years of literature and genuine tripartite pharmacology (Keap1-Nrf2, NF-kappaB, HDAC), scoring on mechanism breadth and indispensable bench utility as the clean Keap1 probe; novelty ceiling is low because the mechanism and most indications are thoroughly characterized, but real multi-indication clinical signal in ASD and metabolic disease keeps it solidly established-active rather than just a workhorse.

Isothiocyanate organosulfur compound and potent Nrf2 pathway activator derived from glucoraphanin in cruciferous vegetables

A dietary isothiocyanate first isolated from broccoli at Johns Hopkins University as the most potent naturally occurring inducer of mammalian phase 2 cytoprotective enzymes, now established as a multimechanistic agent acting through Keap1-Nrf2 electrophilic signaling, NF-kappaB suppression, and histone deacetylase inhibition across chemopreventive, metabolic, neurobehavioral, and anti-inflammatory research applications.

Abstract

Sulforaphane (1-isothiocyanato-4-methylsulfinylbutane) is a low-molecular-weight isothiocyanate generated by myrosinase-catalyzed hydrolysis of the glucosinolate glucoraphanin, found at highest concentration in broccoli sprouts and at progressively lower concentration in mature broccoli, Brussels sprouts, cauliflower, and other cruciferous vegetables. First identified in 1992 by Paul Talalay and colleagues at the Johns Hopkins University School of Medicine as the most potent naturally occurring inducer of mammalian phase 2 detoxification enzymes, sulforaphane has become the most extensively studied dietary isothiocyanate in human pharmacology and the reference compound for nutrigenomic Nrf2 activation. The primary molecular mechanism is electrophilic modification of reactive cysteine residues on the Kelch-like ECH-associated protein 1 (Keap1) sensor, leading to stabilization and nuclear translocation of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and subsequent transcriptional upregulation of a battery of cytoprotective genes including NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), glutathione S-transferases (GSTs), and thioredoxin reductase. Sulforaphane activates Nrf2 with a potency approximately 13-fold greater than curcumin, 18-fold greater than silymarin, and over 100-fold greater than resveratrol in standardized NQO1 inducer assays. A second established mechanism is the suppression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling through inhibition of IkappaB-alpha phosphorylation and degradation, producing broad anti-inflammatory activity. A third mechanism, characterized by Myzak et al. in 2004, is inhibition of histone deacetylase (HDAC) enzymes by the mercapturic acid pathway metabolites sulforaphane-cysteine and sulforaphane-N-acetylcysteine, producing epigenetic reactivation of tumor suppressor genes including p21 and Bax. Pharmacokinetics in humans are characterized by rapid oral absorption (peak plasma concentration within 1 to 3 hours), a short elimination half-life of approximately 1.8 to 2.2 hours, extensive metabolism through the mercapturic acid (glutathione conjugation) pathway, and urinary excretion of 60 to 80 percent of administered sulforaphane equivalents within 24 hours. Oral bioavailability of free sulforaphane is approximately 70 to 80 percent, while bioavailability from the glucoraphanin precursor is approximately 10 to 40 percent depending on myrosinase activity and interindividual variation in gut microbial glucosinolate hydrolysis. Over 80 interventional clinical trials have examined sulforaphane or sulforaphane-yielding preparations in human subjects across indications including cancer chemoprevention (prostate, breast, lung, colorectal, bladder), autism spectrum disorder, type 2 diabetes, schizophrenia, chronic obstructive pulmonary disease, Helicobacter pylori infection, and air pollution detoxification. The Singh et al. (2014) randomized placebo-controlled trial in young men with moderate to severe autism spectrum disorder demonstrated substantial and reversible behavioral improvement on the Aberrant Behavior Checklist and Social Responsiveness Scale after 18 weeks of daily sulforaphane administration. The Axelsson et al. (2017) trial in obese patients with dysregulated type 2 diabetes demonstrated reduced fasting blood glucose and improved glycated hemoglobin with concentrated broccoli sprout extract. The compound is generally well tolerated; the principal adverse events are mild gastrointestinal disturbance (flatulence, bloating, loose stools). Goitrogenic potential at high doses is a theoretical concern for individuals with pre-existing thyroid dysfunction. This monograph reviews the chemistry, biosynthesis, and stereochemistry of sulforaphane; the tripartite molecular pharmacology (Keap1-Nrf2, NF-kappaB, HDAC); comprehensive human pharmacokinetics; the preclinical and clinical evidence base across chemopreventive, metabolic, neurobehavioral, and anti-inflammatory indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a comparative assessment of five alternative Nrf2-activating or cruciferous-derived cytoprotective compounds against sulforaphane on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1496Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Isothiocyanate / NRF2 activator

Sulforaphane

Abstract

Read the full monograph